Kensey Nash’s next-gen TriActiv
This article was originally published in The Gray Sheet
Executive Summary
Firm prepares for upcoming launch of its TriActiv FX embolic protection system after announcing 510(k) clearance for the next-generation system July 12. Compelling results from the company's ASPIRE trial - in which use of TriActiv FX was associated with a comparatively low major adverse cardiac event rate of 3.2% - along with a new rapid exchange system and unique inflation device will help distinguish the balloon-based system from competing devices, Kensey Nash suggests (1"The Gray Sheet" March 13, 2006, In Brief)...